https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-11-07 16:32:542016-11-25 16:33:262013 EHA: Outcomes of intermediate or high risk MDS patients post azacitidine and or decitabine
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-11-06 16:33:312016-11-25 16:33:522013 AACR: Novel Small Molecule DNA Methylation Inhibitor SGI-110 as Ovarian Cancer Chemosensitizer
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-11-04 16:34:012016-11-25 16:34:262013 AACR: In vivo immunomodulatory activity of SGI-110, a second generation hypomethylating agent
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2013-11-02 16:34:562016-11-25 16:35:202013 TAT: IMMUNOMODULATORY ACTIVITY OF SGI-110, A SECOND GENERATION HYPOMETHYLATING AGENT
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-11-25 16:36:202016-11-25 16:38:002012 ASH: Results from Dose Escalation Phase of Randomized Phase 1-2 FIH Study of SGI-110
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2012-11-23 16:38:392016-11-25 16:38:582012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer